Chronic dialysis patients with end stage renal disease have an increased mortality rate as compared to the age matched healthy population. It is known that chronic inflammation contributes to the high incidence of cardiovascular events in chronic dialysis patients. Dialyzers made by membranes with increased pore size (high cut-off Dialyzer HCO1100) may be beneficial in the elimination of inflammatory mediators and may improve the inflammatory status. Hypothesis: In this study it will be investigated whether the treatment with HCO1100 will improve the inflammatory status of chronic dialysis patients.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
50
KfH Bachstzelzenweg 4
Halle, Saxony-Anhalt, Germany
KfH-Bismarkstrasse 95-96
Berlin, Germany
change of CD162 expression on monocytes
change of CD162 expression on monocytes, timepoints in each treatment phase: 1.)1st.day (prae dialysis) 2.)1st.day (post dialysis) 3.)2nd.day (prae dialysis) 4.)8th.day (prae dialysis) 5.)15th.day (prae dialysis) 6.)22nd.day (prae dialysis)
Time frame: 8 weeks (3 weeks treatment phase, 2 weeks wash out phase, 3 weeks treatment phase)
Albumin blood level
change of albumin blood level, timepoints in each treatment phase: 1.)1st.day (prae dialysis) 2.)1st.day (post dialysis) 3.)2nd.day (prae dialysis) 4.)8th.day (prae dialysis) 5.)15th.day (prae dialysis) 6.)22nd.day (prae dialysis)
Time frame: 8 weeks (3 weeks treatment phase, 2 weeks wash out phase, 3 weeks treatment phase)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.